PEG & ADCs
- Maytansinoids as Payloads of ADCs: DM1, DM4
- Antibody-drug Conjugates for HER2-Positive Gastric Cancer
- c-MET: A Novel Target for Anticancer Therapies
- Novel FRα-targeting Antibody-drug Conjugates (ADCs)
- Nectin-4-Directed Drugs for Solid Tumors
- Claudin18.2 Targeted Therapies In Cancer
- FDA Approves Tivdak - First Tissue Factor (TF)-Targeted Antibody Conjugate Drug (ADC)
- ADC Drugs Global Sales of 2021 and Future Prospects
- Global Sales of ADCs in 2022 – UP to 7 Billion
- Clinical Development of ADC Drugs Targeting TROP-2